2m 2m 2m 2m 2m 2m 2m
Aldeyra Therapeu (ALDX)
NASDAQ
$1.85-$0.01 (-0.59%)
Price as of Jun 03, 2026 7:59 PM EDT- $105.6MMarket Cap
- -30.21%1-Year Change
- BiotechnologyIndustry
Aldeyra Therapeu (ALDX)
$1.85-$0.01 (-0.59%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 N/A | 0 N/A | 0 N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -25.7M -46.78% | -48.2M +63.70% | -29.5M -37.73% | -47.3M +5.27% | |
Depreciation and Amortization Expense | 251,993 +0.95% | 249,623 -5.01% | 262,780 +1.57% | 258,707 -2.07% | |
Total Operating Expenses | 9.6M -19.26% | 11.9M -10.82% | 13.3M -13.26% | 15.4M +36.26% | |
Operating Profit | -35.3M -41.34% | -60.1M +40.48% | -42.8M -31.73% | -62.7M +11.49% | |
Interest Income | 3.3M -46.32% | 6.2M -15.45% | 7.3M +211.69% | 2.3M +1,167.49% | |
Interest Expense | N/A N/A | N/A N/A | -2.1M +22.27% | -1.7M -2.76% | |
Interest Income and Expense and Net | 3.3M -46.32% | 6.2M +17.90% | 5.3M +701.34% | 655,351 +142.10% | |
Total Nonoperating Income and Expense | 1.4M -66.74% | 4.3M -18.78% | 5.3M +701.34% | 655,351 +142.10% | |
Income before Taxes | -35.3M -41.34% | -60.1M +40.48% | -42.8M -31.73% | -62.7M +8.49% | |
Income Taxes | 0 -100.00% | 1,000 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -33.8M -39.40% | -55.9M +48.77% | -37.5M -39.47% | -62.0M +7.35% | |
Net Income from Continuing Operations Applicable to Common | -33.8M -39.40% | -55.9M +48.77% | -37.5M -39.47% | -62.0M +7.35% | |
Basic EPS and Net Income | -0.56 -40.43% | -0.94 +46.88% | -0.64 -39.62% | -1.06 -0.93% | |
Diluted EPS and Net Income | -0.56 -40.43% | -0.94 +46.88% | -0.64 -39.62% | -1.06 -0.93% | |
Basic Weighted Average Shares | 60.1M +0.96% | 59.5M +0.92% | 58.9M +0.92% | 58.4M +8.07% | |
Diluted Weighted Average Shares | 60.1M +0.96% | 59.5M +0.92% | 58.9M +0.92% | 58.4M +8.07% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 70.0M +28.45% | 54.5M -61.82% | 142.8M -1.11% | 144.4M -37.15% | |
Short-Term Investments | 0 -100.00% | 46.6M N/A | 0 -100.00% | 29.9M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 70.0M -30.76% | 101.2M -29.18% | 142.8M -18.06% | 174.3M -24.15% | |
Total Current Assets | 71.8M -31.03% | 104.1M -29.59% | 147.8M -18.35% | 181.0M -22.23% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | 0 -100.00% | 5,764 -70.10% | 19,279 -40.66% | |
Total Long-Term Assets | 0 -100.00% | 267,261 +4,536.73% | 5,764 -70.10% | 19,279 -40.66% | |
Total Assets | 72.1M -31.11% | 104.6M -29.48% | 148.3M -18.18% | 181.3M -22.24% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 15.2M +48,509.05% | 31,372 -99.79% | 15.1M +1,561.24% | 911,763 N/A | |
Total Current Liabilities | 27.8M +49.50% | 18.6M -16.43% | 22.3M +44.92% | 15.4M +30.48% | |
Total Long-Term Debt | 0 -100.00% | 15.0M N/A | 0 -100.00% | 14.9M -3.74% | |
Total Long-Term Liabilities | 0 -100.00% | 15.0M +5,422.20% | 271,631 -98.18% | 14.9M -4.52% | |
Total Liabilities | 27.8M -17.24% | 33.6M +17.77% | 28.5M -5.78% | 30.3M +10.52% | |
Retained Earnings | -484.0M +7.52% | -450.1M +14.17% | -394.3M +10.52% | -356.7M +21.05% | |
Total Stockholders Equity | 44.3M -37.68% | 71.0M -40.73% | 119.8M -20.67% | 151.0M -26.60% | |
Total Shares Outstanding | 60.2M +0.86% | 59.6M +0.76% | 59.2M +1.09% | 58.6M +0.82% | |
Cash Flow | |||||
Cash from Operating Activities | -33.3M -22.83% | -43.2M +42.48% | -30.3M -46.46% | -56.6M +33.09% | |
Capital Expenditures | N/A N/A | N/A N/A | 0 -100.00% | 16,317 +109.03% | |
Cash from Investing Activities | 47.7M +206.28% | -44.9M -249.72% | 30.0M +200.15% | -30.0M +383,637.25% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 1.1M +755.43% | -171,422 -86.50% | -1.3M -204.11% | 1.2M -99.37% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -38.32% -13.24% | -44.16% +93.87% | -22.78% -23.90% | -29.93% -18.02% | |
Return on Equity | -58.73% +0.32% | -58.54% +111.15% | -27.73% -20.26% | -34.77% -20.18% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 2.58 -53.86% | 5.59 -15.74% | 6.64 -43.66% | 11.78 -40.39% | |
Cash Ratio | 2.52 -14.08% | 2.93 -54.31% | 6.42 -31.76% | 9.40 -51.83% | |
Debt-to-Equity Ratio | 0.34 +62.78% | 0.21 +67.48% | 0.13 +20.50% | 0.10 +39.12% | |
Debt-to-Assets Ratio | 0.21 +47.25% | 0.14 +40.74% | 0.10 +16.95% | 0.09 +31.28% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow